Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
Research & Development
Innovent Biologics Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥12.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Research & Development
-¥1.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
S
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Research & Development
-¥177.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Research & Development
-¥988.6m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Research & Development
-¥168.2m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
See Also
What is Innovent Biologics Inc's Research & Development?
Research & Development
-2.1B
CNY
Based on the financial report for Dec 31, 2023, Innovent Biologics Inc's Research & Development amounts to -2.1B CNY.
What is Innovent Biologics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was 26%. The average annual Research & Development growth rates for Innovent Biologics Inc have been -4% over the past three years , -12% over the past five years .